Seragon Pharmaceuticals Names Former Onyx Pharmaceuticals CEO to its BoardMonday, March 24, 2014
Newly formed Seragon Pharmaceuticals Inc. has appointed N. Anthony Coles, the former CEO and board chairman of Onyx Pharmaceuticals Inc., to its board of directors.
San Diego-based Seragon develops breast cancer therapies. Bay Area-based Onyx was bought out by Los Angeles’ Amgen Inc. for $10.4 billion last October.
Seragon was spun off last August from Aragon Pharmaceuticals Inc., which was bought by Johnson & Johnson (NYSE: JNJ) in a deal worth up to $1 billion. Seragon raised $30 million in Series A financing in October, largely from the same investor group that founded Aragon.
Aragon developed a treatment for prostate cancer, and Onyx also developed cancer treatments.
Coles’ experience in leading a successful company focused on cancer treatments will make him “an invaluable member” of the board, Seragon CEO Richard Heyman said.